Novo Nordisk has acquired Cardior Pharmaeuticals for up to €1.025 billion, including an upfront payment and additional payments if certain milestones are achieved. Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. The company seeks to advance a novel class of antisense […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!